Boston Scientific Corporation (NYSE:BSX) Executive Vice President of Human Resources, Carruthers Wendy, has sold shares worth $517,579, according to a recent SEC filing. The transaction was executed on August 1, 2024, at a price of $74.12 per share, totaling 6983 shares of the company's common stock.
On the same day, the filing also revealed that Wendy acquired a total of 4263 shares through option exercises, with prices ranging between $17.26 and $24.55, amounting to $82,305. These transactions were part of a pre-established trading plan under Rule 10b5-1, which allows insiders to set up a predetermined plan to buy or sell company stock.
The sale of shares by Carruthers Wendy follows the exercise of stock options that were set to vest in four equal annual installments, with the first vesting dates being February 22, 2017, and February 28, 2018, respectively. These options were part of the executive's compensation and incentive plan.
After the reported transactions, Wendy's (NASDAQ:WEN) ownership in Boston Scientific Corporation stands at 40,188 shares of common stock directly held. The company, headquartered in Marlborough, Massachusetts, specializes in the manufacturing of medical devices used in interventional medical specialties.
Investors and market watchers often pay close attention to insider transactions as they can provide insights into the executive's perspective on the company's current valuation and future prospects. However, it's important to note that insider trading activity is subject to strict regulations and reporting requirements to prevent any potential misuse of non-public information.
Boston Scientific Corporation's stock performance and insider transactions are routinely monitored by investors to gauge the company's health and the confidence that executives have in their firm's future.
In other recent news, Boston Scientific's earnings and revenue results have surpassed expectations. The company reported a 14.5% year-over-year increase on a reported basis in revenue, reaching $4,120 million. Adjusted earnings per share (EPS) stood at $0.62, outperforming estimates. In light of these robust results, Boston Scientific has uplifted its full-year 2024 guidance, now projecting a growth range of 13.5% to 14.5%.
Canaccord Genuity and Deutsche Bank (ETR:DBKGn) have both updated their outlooks on Boston Scientific. Canaccord Genuity raised its stock price target to $88 from $83, while Deutsche Bank increased its price target to $78 from $73. Both firms maintain a positive outlook on the company, citing factors such as successful product launches and strategic acquisitions.
Boston Scientific's growth is attributed to several factors, including the success of Farapulse, anticipated catalysts, and the company's focus on mergers and acquisitions. Recent developments include the pending acquisitions of AXNX and SILK, the expected approval for modular CRM systems in 2025, and the launch of Farapulse in Japan and China in 2025 and the second half of 2024 respectively. The company also anticipates additional growth opportunities with likely add-on reimbursement for Farapulse in the fourth quarter of 2024.
InvestingPro Insights
As Boston Scientific Corporation (NYSE:BSX) navigates through its financial journey, recent data from InvestingPro provides a snapshot of the company's current market position. With a robust market capitalization of approximately $110.01 billion, Boston Scientific stands as a significant player in the healthcare equipment and supplies industry. The company's P/E ratio, a measure of its current share price relative to its per-share earnings, is at 59.9, which adjusts to 53.16 when considering the last twelve months as of Q2 2024. This figure indicates the market's valuation of the company in relation to its earnings power.
The growth trajectory for Boston Scientific also appears positive, with revenue growth reaching 13.65% in the last twelve months as of Q2 2024. This is further supported by an InvestingPro Tip highlighting that net income is expected to grow this year, which can be an encouraging sign for potential investors. Moreover, the company's gross profit margin stands at a healthy 68.79%, showcasing its ability to maintain profitability despite the costs of goods sold.
Additionally, Boston Scientific's stock has been trading near its 52-week high, with the price at 94.62% of this peak, reflecting strong investor confidence. This is complemented by an InvestingPro Tip that points out the stock's generally low price volatility, which could suggest a stable investment for those looking to avoid significant market swings.
For those interested in exploring more about Boston Scientific's financial health and investment potential, InvestingPro offers a total of 16 additional tips on their platform. These insights could provide valuable information for making informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.